May 22, 2017

Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop

March 6, 2017

Attune Pharmaceuticals Announces Pre-Clinical Data for ATN-249, An Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at AAAAI

March 1, 2017

Attune Pharmaceuticals Announces Late-Breaking Poster Presentation of ATN-249, an Oral Kallikrein Inhibitor for the Treatment of HAE

May 22, 2017

Safety Study of ATN-249, A New Oral Kallikrein Inhibitor for Hereditary Angioedema

March 6, 2017

Selectivity, Potency, and Exposure Evaluation of ATN-249, A New Oral Kallikrein Inhibitor for Hereditary Angioedema